Guardant Health, Inc. (GH)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$161.41+0.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · GH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 1.1% |
| Our one-year growth estimate | diamond | 39.3% |
Growth built into the price is above our model estimate.
The price assumes 38.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 32 industry peers · Company calendar date is not available
GH — earnings miss
Dated 2026-07-30
Results of Operations and Financial Condition. On July 30, 2026, Guardant Health, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities…
Why it matters: The CMO leaving might change product plans and how they are carried out. This creates uncertainty.
Worry ifNo bad changes in operations have been reported since the CMO left.
Less concerning ifThere have been reports of problems or changes in strategy after the CMO left.
Why it matters: This would indicate that Guardant is not on track to meet its updated revenue guidance for 2026.
Worry ifQ3 revenue growth reported below 36% year over year.
Less concerning ifQ3 revenue growth meets or exceeds 36% year over year.
Why it matters: A further increase in revenue guidance would show strong momentum in the business.
Supportive ifRevenue guidance raised above $1.36 billion for 2026.
Worry ifRevenue guidance remains at $1.34 to $1.36 billion without an increase.
Why it matters: The earnings report will show if the company can improve its financial performance. Investors will look for signs of recovery.
Watch forEarnings report shows revenue growth above 10% year over year.
Also watch forEarnings report shows revenue decline or flat growth year over year.
Why it matters: A new CMO could impact strategy and operations. This is important after the recent departure.
Watch forA new Chief Medical Officer was announced. This person has the right experience.
Also watch forNo appointment is made within the next three months, causing uncertainty.
Why it matters: Going above this level means cash burn is getting worse. This raises worries about finances.
Worry ifFree cash flow burn reported above $205 million for 2026.
Less concerning ifFree cash flow burn reported at or below $195 million for 2026.
Why it matters: More Shield tests mean the market likes the product. This shows good money-making chances.
Supportive ifShield screening test volume exceeds 70,000 tests in Q3.
Worry ifShield screening test volume falls below 66,000 tests in Q3.
Why it matters: Going above this number shows strong demand. It means the Shield test is doing well.
Supportive ifShield screening revenue reported above $230 million for 2026.
Worry ifShield screening revenue reported below $218 million for 2026.
Why it matters: This revenue shows that many people are using the Shield screening tests. It shows good marketing and partnerships.
Supportive ifScreening revenue of $186 million or more for 2026.
Worry ifScreening revenue falls below $162 million for 2026.
Why it matters: Dropping below this level may show cost problems. This could hurt profits.
Worry ifQ3 non-GAAP gross margin reported below 64%.
Less concerning ifQ3 non-GAAP gross margin reported at or above 64%.
Why it matters: This change may affect the company's plans and actions. It could change how investors feel.
Worry ifGood news about new leaders or plans after the departure.
Less concerning ifNegative news or setbacks related to the CMO's departure.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$197 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $457 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,298 loss on $10,000 · 33.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.